This website uses cookies
Read our Privacy policy and Terms of use for more information.
Apr 23, 2026
Big Pharma is going full AI mode... and Merck just dropped $1B to prove it.
Apr 21, 2026
Psychedelics get the fast lane, peptides stir controversy, and Lilly's $7B CAR-T deal.
Apr 16, 2026
Novo bets big on AI, pharma earnings season is here, and M&A is surging. Biotech is anything but quiet right now.
Apr 14, 2026
One CAR-T therapy, three diseases gone. Plus: biotech’s next trillion-dollar molecule.
Apr 9, 2026
FDA pushes for stronger ad oversight, Gilead continues its deal spree, and a two-person AI startup sparks controversy with $1.8B projections.
Apr 7, 2026
Pharma tariffs shake the market, Anthropic drops $400M on biotech, and a Lilly vs. Novo deep dive
Apr 2, 2026
GLP-1 pill wars heat up, billion-dollar deals fly, and the FDA faces a stacked Q2
Mar 31, 2026
ACIP chaos, Lilly’s $2.75B AI bet, and a biotech policy fight that’s heating up fast.
Mar 19, 2026
This story and more in the March 19, 2026 issue
